Maa: Kanada
Kieli: englanti
Lähde: Health Canada
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
VITA HEALTH PRODUCTS INC
M01AE51
IBUPROFEN, COMBINATIONS
200MG; 30MG
TABLET
IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG
ORAL
10/20/24/40/50/72/96/100
OTC
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0222394001; AHFS:
APPROVED
2011-02-08
PRODUCT MONOGRAPH COLD + SINUS DAYTIME Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg Caplets Analgesic/Antipyretic/Nasal Decongestant COLD + SINUS NIGHTTIME Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg and Chlorpheniramine Maleate 2 mg Tablets Analgesic/Antipyretic/Nasal Decongestant/Antihistamine Vita Health Products Inc. Date of Revision: 150 Beghin Avenue October 19, 2020 Winnipeg, Manitoba Canada, R2J 3W2 Control # 239435 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION .............................................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................................... 3 CONTRAINDICATIONS ......................................................................................................................... 4 WARNINGS AND PRECAUTIONS ....................................................................................................... 5 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ........................................................................................................................ 23 DOSAGE AND ADMINISTRATION .................................................................................................... 27 OVERDOSAGE ...................................................................................................................................... 28 ACTION AND CLINICAL PHARMACOLOGY .................................................................................. 31 STORAGE AND STABILITY ............................................................................................................... 36 SPECIAL HANDLING INSTRUCTIONS .................................... Lue koko asiakirja